{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:17:25Z","timestamp":1794568645292,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As treatment strategies for early triple-negative breast cancer continue to evolve, translating clinical evidence into practice can be challenging, especially as the standard of care also shifts and may differ across studies. The management of patients with triple-negative breast cancer who have residual disease after neoadjuvant therapy exemplifies a complex clinical scenario with emerging yet sometimes difficult-to-interpret evidence. Through a critical appraisal of current data and an expert consensus discussion from the Nordic region, the authors present a perspective on postneoadjuvant treatment options for triple-negative breast cancer and discuss potential approaches based on available evidence and expert opinion.<\/jats:p>","DOI":"10.1038\/s41416-026-03452-8","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:59:31Z","timestamp":1777460371000},"page":"329-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insights on postneoadjuvant treatment among patients with triple-negative breast cancer and residual disease after neoadjuvant therapy: can expert consensus help to interpret the current evidence?"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-0194","authenticated-orcid":false,"given":"Antonis","family":"Valachis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6239-3856","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-3702","authenticated-orcid":false,"given":"Peeter","family":"Karihtala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata K.","family":"Tuxen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"3452_CR1","doi-asserted-by":"publisher","first-page":"e390464","DOI":"10.1200\/EDBK_390464","volume":"43","author":"HS Han","year":"2023","unstructured":"Han HS, Vikas P, Costa RLB, Jahan N, Taye A, Stringer-Reasor EM. Early-stage triple-negative breast cancer journey: beginning, end, and everything in between. Am Soc Clin Oncol Educ Book. 2023;43:e390464.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3452_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. KEYNOTE-522 investigators. overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981\u201391.","journal-title":"N Engl J Med"},{"key":"3452_CR3","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359.","journal-title":"N Engl J Med"},{"key":"3452_CR4","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al.OlympiA Clinical Trial Steering Committee and Investigators Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250\u201368.","journal-title":"Ann Oncol"},{"key":"3452_CR5","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.00976","volume":"39","author":"IA Mayer","year":"2021","unstructured":"Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021;39:2539\u201351.","journal-title":"J Clin Oncol"},{"key":"3452_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1200\/JCO.21.01657","volume":"40","author":"BP Schneider","year":"2022","unstructured":"Schneider BP, Jiang G, Ballinger TJ, Shen F, Chitambar C, Nanda R, et al. BRE12-158: A postneoadjuvant, randomized phase II trial of personalized therapy versus treatment of physician\u2019s choice for patients with residual triple-negative breast cancer. J Clin Oncol. 2022;40:345\u201355.","journal-title":"J Clin Oncol"},{"key":"3452_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","volume":"35","author":"L Pusztai","year":"2024","unstructured":"Pusztai L, Denkert C, O\u2019Shaughnessy J, Cortes J, Dent R, McArthur H, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol. 2024;35:429\u201336.","journal-title":"Ann Oncol"},{"key":"3452_CR8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1001\/jama.2024.26886","volume":"333","author":"M Ignatiadis","year":"2025","unstructured":"Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, et al. Adjuvant atezolizumab for early triple-negative breast cancer: the ALEXANDRA\/IMpassion030 randomized clinical trial. JAMA. 2025;333:1150\u201360.","journal-title":"JAMA"},{"key":"3452_CR9","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.annonc.2025.08.005","volume":"36","author":"PF Conte","year":"2025","unstructured":"Conte PF, Dieci MV, Bisagni G, Schmid P, Zambelli A, Piacentini F, et al. A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients. Ann Oncol. 2025;36:1492\u2013502.","journal-title":"Ann Oncol"},{"key":"3452_CR10","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052\u201361.","journal-title":"Cancer Res"},{"key":"3452_CR11","doi-asserted-by":"publisher","first-page":"zcaa002","DOI":"10.1093\/narcan\/zcaa002","volume":"2","author":"C Bailly","year":"2020","unstructured":"Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020;2:zcaa002.","journal-title":"NAR Cancer"},{"key":"3452_CR12","doi-asserted-by":"publisher","first-page":"2527303","DOI":"10.1080\/2162402X.2025.2527303","volume":"14","author":"MO Gbadamosi","year":"2025","unstructured":"Gbadamosi MO, Molchan E, Makarem MS, Coleman KL, Ohaegbulam AC, Streeks KH. Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy. Oncoimmunology. 2025;14:2527303.","journal-title":"Oncoimmunology"},{"key":"3452_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","volume":"35","author":"R Dent","year":"2024","unstructured":"Dent R, Andr\u00e9 F, Gon\u00e7alves A, Martin M, Schmid P, Sch\u00fctz F, et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024;35:630\u201342.","journal-title":"Ann Oncol"},{"key":"3452_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000173","volume":"8","author":"AN Shah","year":"2020","unstructured":"Shah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, et al. Phase II study of pembrolizumab and capecitabine for triple-negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8:e000173.","journal-title":"J Immunother Cancer"},{"key":"3452_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00541-2","volume":"9","author":"DB Page","year":"2023","unstructured":"Page DB, Pucilowska J, Chun B, Kim I, Sanchez K, Moxon N, et al. A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st\/2nd line metastatic triple-negative breast cancer. NPJ Breast Cancer. 2023;9:53.","journal-title":"NPJ Breast Cancer"},{"key":"3452_CR16","unstructured":"UNICANCER. Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05973864 (Accessed 19th October 2025)."},{"key":"3452_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8:1751.","journal-title":"Nat Commun"},{"key":"3452_CR18","first-page":"1585170","volume":"6","author":"RM Chabanon","year":"2019","unstructured":"Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S. Beyond DNA repair: the novel immunological potential of PARP inhibitors. Mol Cell Oncol. 2019;6:1585170.","journal-title":"Mol Cell Oncol"},{"key":"3452_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-022-06780-4","volume":"197","author":"T Gupta","year":"2023","unstructured":"Gupta T, Vinayak S, Telli M. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Res Treat. 2023;197:51\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"3452_CR20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 2020;21:1155\u201364.","journal-title":"Lancet Oncol"},{"key":"3452_CR21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"8","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;8:1132\u201340.","journal-title":"JAMA Oncol"},{"key":"3452_CR22","doi-asserted-by":"publisher","first-page":"GS01-05","DOI":"10.1158\/1538-7445.SABCS23-GS01-05","volume":"84","author":"H Rugo","year":"2024","unstructured":"Rugo H, Robson M, Im S-A, Dalenc F, Ya\u00f1ez Ruiz E, Im Y-H, et al. Pembrolizumab + Olaparib vs Pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: randomized open-label phase 2 KEYLYNK-009 study. Cancer Res. 2024;84:GS01-05.","journal-title":"Cancer Res"},{"key":"3452_CR23","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41416-022-01711-y","volume":"126","author":"LW de Boo","year":"2022","unstructured":"de Boo LW, J\u00f3\u017awiak K, Joensuu H, Lindman H, Lauttia S, Opdam M, et al. Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. Br J Cancer. 2022;126:1401\u20139.","journal-title":"Br J Cancer"},{"key":"3452_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2011.35.4639","volume":"30","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30:11\u20138.","journal-title":"J Clin Oncol"},{"key":"3452_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"3452_CR26","doi-asserted-by":"publisher","first-page":"101389","DOI":"10.1016\/j.esmoop.2023.101389","volume":"8","author":"M Robson","year":"2023","unstructured":"Robson M, Delaloge S, Domchek SM, Conte PF, Im S-A, Xu B, et al. OlympiAD: exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC). ESMO Open. 2023;8:101389.","journal-title":"ESMO Open"},{"key":"3452_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2340\/1651-226X.2025.42733","volume":"64","author":"A Valachis","year":"2025","unstructured":"Valachis A, Karihtala P, Geisler J, Tuxen MK. Metastatic triple-negative breast cancer - current treatment strategies in the Nordics: a modified Delphi study. Acta Oncol. 2025;64:349\u201357.","journal-title":"Acta Oncol"},{"key":"3452_CR28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, et al.St Gallen Consensus Conference Panelists 2023 Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34:970\u201386.","journal-title":"Ann Oncol"},{"key":"3452_CR29","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3390\/cancers13092262","volume":"13","author":"H Elghazaly","year":"2021","unstructured":"Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, et al. Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers. 2021;13:2262.","journal-title":"Cancers"},{"key":"3452_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10250-x","volume":"22","author":"R Freitas-Junior","year":"2022","unstructured":"Freitas-Junior R, de Oliveira VM, Frasson AL, Cavalcante FP, Mansani FP, Mattar A, et al. Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology. BMC Cancer. 2022;22:1201.","journal-title":"BMC Cancer"},{"key":"3452_CR31","doi-asserted-by":"publisher","first-page":"1507840","DOI":"10.3389\/fonc.2025.1507840","volume":"15","author":"YH Park","year":"2025","unstructured":"Park YH, Lee SC, Singer CF, Balma\u00f1a J, Dent RA, Tan VK, et al. Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management. Front Oncol. 2025;15:1507840.","journal-title":"Front Oncol"},{"key":"3452_CR32","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.amjmed.2019.02.005","volume":"132","author":"J Mandrola","year":"2019","unstructured":"Mandrola J, Cifu A, Prasad V, Foy A. The case for being a medical conservative. Am J Med. 2019;132:900\u20131.","journal-title":"Am J Med"},{"key":"3452_CR33","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","volume":"179","author":"B Gyawali","year":"2019","unstructured":"Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med. 2019;179:906\u201313.","journal-title":"JAMA Intern Med"},{"key":"3452_CR34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","volume":"16","author":"CM Booth","year":"2019","unstructured":"Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16:312\u201325.","journal-title":"Nat Rev Clin Oncol"},{"key":"3452_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","volume":"176","author":"TU Schulz","year":"2022","unstructured":"Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients\u2019 health-related quality of life. Eur J Cancer. 2022;176:88\u201399.","journal-title":"Eur J Cancer"},{"key":"3452_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.CCR-22-2191","volume":"29","author":"K Asleh","year":"2023","unstructured":"Asleh K, Lluch A, Goytain A, Barrios C, Wang XQ, Torrecillas L, et al. Triple-negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Clin Cancer Res. 2023;29:389\u2013400.","journal-title":"Clin Cancer Res"},{"key":"3452_CR37","doi-asserted-by":"publisher","first-page":"TPS602","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS602","volume":"39","author":"F Marm\u00e9","year":"2021","unstructured":"Marm\u00e9 F, Stickeler E, Furlanetto J, et al. Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. J Clin Oncol. 2021;39:TPS602.","journal-title":"J Clin Oncol"},{"key":"3452_CR38","doi-asserted-by":"publisher","first-page":"175883592412483","DOI":"10.1177\/17588359241248336","volume":"16","author":"A Bardia","year":"2024","unstructured":"Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, et al. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024;16:17588359241248336.","journal-title":"Ther Adv Med Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03452-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03452-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03452-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:30:37Z","timestamp":1784104237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03452-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,5]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03452-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AV: unrestricted institutional grant from Roche and MSD. JG: No conflict of interests to declare. PK: member of the advisory board, speaker, or expert testimony for Amgen, Astellas, AstraZeneca, Daichii Sankyo, Gilead, Lilly, Menarini Stemline, MSD, Novartis, Pfizer, Roche and Sandoz. MKT: member of the advisory board or consultant for AstraZeneca, Daichii Sankyo, Lilly, Gilead, MSD, Novartis, Pfizer.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}